Melane Sampson, Author at BioTuesdays

Developments

NeuroSense enrolls first patient in Phase 2b ALS Trial with PrimeC

NeuroSense Therapeutics (NASDAQ:NRSN) enrolled the first patient in its Phase 2b PARADIGM trial for its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM will enroll 69...

June 1, 2022

Developments

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress...

May 27, 2022

Executive Moves

MindMed names Schond Greenway as CFO

Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...

May 24, 2022

Developments

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

“We continue to gain confidence in the disruptive potential of Profound Medical’s (NASDAQ:PROF; TSX:PRN) transurethral directional thermal ultrasound ablation treatment for prostate cancer, TULSA-PRO,” writes Cowen...

May 20, 2022

Developments

Profound Medical insiders add to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

May 19, 2022

Developments

Ampio board committee conducting internal investigation

An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...

May 17, 2022

Executive Moves

Soricimed Biopharma adds deep public markets experience to team with appointment of healthcare veteran Frank Michalargias as CFO

Frank Michalargias Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO. In a finance and operations leadership career spanning more than 25...

May 16, 2022

Markets

BTIG slashes 89bio PT to $28 from $60

BTIG reduced its price target for 89bio (NASDAQ:ETNB) to $28 from $60 but maintained its “buy” rating after making model updates and increasing its modeled discount rate to 14% from 12%. The stock closed at $2.67 on May...

May 13, 2022

Developments

NeoTX acquires InterX to boost drug discovery

Closely-held NeoTX of Israel has acquired InterX, a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel...

May 12, 2022

Developments

Check-Cap initiates U.S. pivotal trial of C-Scan

Check-Cap (NASDAQ:CHEK) initiated its U.S. pivotal trial of C-Scan to detect polyps before they become colorectal cancer at the Mayo Clinic in Rochester, Minn. The company has obtained Institutional review board...

May 11, 2022

Author - Melane Sampson

NeuroSense enrolls first patient in Phase 2b ALS Trial with PrimeC

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

MindMed names Schond Greenway as CFO

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

Profound Medical insiders add to holdings

Ampio board committee conducting internal investigation

Soricimed Biopharma adds deep public markets experience to team with appointment of healthcare veteran Frank Michalargias as CFO

BTIG slashes 89bio PT to $28 from $60

NeoTX acquires InterX to boost drug discovery

Check-Cap initiates U.S. pivotal trial of C-Scan

Subscribe